Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0PRHQF |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | h12F3 |
|||||
| Synonyms |
h12F3
Click to Show/Hide
|
|||||
| Antibody Type | Bispecific antibody (BsAb) |
|||||
| Antigen Name | Alkaline phosphatase, germ cell type (ALPG); Alkaline phosphatase, placental type (ALPP) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SGN-ALPV [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05229900 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 study of SGN-ALPV in advanced solid tumors.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible participants must have specified advanced solid tumors (ovarian/endometrial/NSCLC/gastric/cervical/GCT cancers) with measurable disease (RECIST v1.1), ECOG 0-1, and biopsy compliance for biomarker analysis. Key exclusions include active CNS metastases, prior MMAE/ALPP-targeted therapy, or Grade≥2 neuropathy (CTCAE v5.0). Ovarian cancer cohorts require platinum-resistant HGSOC with prior bevacizumab exposure.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05229900 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary endpoints focus on safety evaluation including AE incidence (6 months post-treatment), DLT occurrence (28 days), and laboratory abnormalities, with dose-level toxicity analysis.
|
||||
| Other Endpoint |
Secondary objectives assess immunogenicity (ADA incidence over 6 months), PK parameters (AUC/Cmax/Tmax/t½/Ctrough within 14 days post-treatment), efficacy measures (ORR/DOR/PFS/OS per RECIST v1.1 over 2 years), and ovarian cancer-specific CA-125 responses (GCIG criteria).
|
||||
References